See more : Banpu Power Public Company Limited (BPP-R.BK) Income Statement Analysis – Financial Results
Complete financial analysis of Theratechnologies Inc. (THTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Theratechnologies Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- BASE, Inc. (BAINF) Income Statement Analysis – Financial Results
- CFI-Compagnie Foncière Internationale (CFI.PA) Income Statement Analysis – Financial Results
- Ryoden Corporation (8084.T) Income Statement Analysis – Financial Results
- Choice Hotels International, Inc. (CHH) Income Statement Analysis – Financial Results
- Manufatura de Brinquedos Estrela S.A. (ESTR4.SA) Income Statement Analysis – Financial Results
Theratechnologies Inc. (THTX)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.theratech.com
About Theratechnologies Inc.
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH1902, which is in Phase 1/Part A clinical trials for the treatment of triple negative breast cancer; and TH1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 81.76M | 80.06M | 69.82M | 66.05M | 63.22M | 44.05M | 33.23M | 27.60M | 22.55M | 5.90M | 7.13M | 13.66M |
| Cost of Revenue | 19.64M | 26.28M | 23.26M | 26.90M | 26.08M | 14.68M | 17.15M | 10.14M | 6.70M | 7.07M | 10.46M | 11.47M |
| Gross Profit | 62.13M | 53.78M | 46.56M | 39.15M | 37.14M | 29.38M | 16.07M | 17.47M | 15.85M | -1.17M | -3.33M | 2.18M |
| Gross Profit Ratio | 75.99% | 67.17% | 66.69% | 59.27% | 58.75% | 66.68% | 48.37% | 63.28% | 70.29% | -19.90% | -46.72% | 15.99% |
| Research & Development | 30.37M | 36.94M | 28.27M | 18.02M | 10.84M | 7.77M | 9.19M | 5.65M | 4.11M | 4.95M | 7.09M | 7.08M |
| General & Administrative | 15.62M | 17.36M | 14.62M | 12.23M | 8.33M | 5.83M | 4.51M | 3.57M | 2.99M | 4.00M | 3.55M | 5.50M |
| Selling & Marketing | 26.77M | 39.39M | 28.91M | 26.86M | 26.48M | 21.69M | 20.17M | 10.86M | 9.66M | 6.10M | 236.05K | 857.67K |
| SG&A | 42.39M | 56.75M | 43.53M | 39.09M | 34.81M | 25.02M | 24.67M | 14.54M | 12.74M | 10.10M | 3.84M | 6.36M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 850.00K | 22.07M |
| Operating Expenses | 72.76M | 93.69M | 71.80M | 57.11M | 45.65M | 32.79M | -30.64M | -16.76M | -14.28M | -8.21M | -901.69K | -16.97M |
| Cost & Expenses | 92.39M | 119.97M | 95.06M | 84.01M | 71.73M | 47.47M | -13.48M | -6.63M | -7.58M | -1.14M | 9.56M | -5.50M |
| Interest Income | 0.00 | 316.00K | 195.00K | 299.00K | 1.10M | 285.00K | 261.99K | 77.44K | 30.76K | 173.52K | 429.60K | 762.04K |
| Interest Expense | 10.55M | 6.50M | 5.66M | 5.36M | 4.99M | 2.53M | 1.07M | 1.44M | 1.87M | 1.05M | 12.25K | 23.12K |
| Depreciation & Amortization | 3.30M | 12.03M | 8.58M | 8.84M | 7.50M | 4.14M | 1.55M | 1.57M | 1.44M | 1.00M | 114.25K | 567.75K |
| EBITDA | -10.31M | -27.87M | -17.16M | -9.18M | 28.01K | 731.32K | -11.68M | 3.79M | 4.55M | -6.68M | -7.06M | -3.60M |
| EBITDA Ratio | -12.61% | -33.92% | -23.38% | -13.89% | 0.06% | 1.66% | -21.24% | 16.31% | 20.17% | -113.15% | -98.94% | -26.39% |
| Operating Income | -10.63M | -39.91M | -25.24M | -17.96M | -8.51M | -3.41M | -8.60M | 2.93M | 3.11M | -7.68M | -7.17M | -4.17M |
| Operating Income Ratio | -13.00% | -49.85% | -36.14% | -27.19% | -13.47% | -7.75% | -25.89% | 10.62% | 13.79% | -130.11% | -100.54% | -30.54% |
| Total Other Income/Expenses | -12.91M | -6.89M | -6.43M | -4.69M | -3.98M | -2.56M | -5.72M | -2.15M | -1.50M | -1.53M | 3.37M | -9.86M |
| Income Before Tax | -23.54M | -46.79M | -31.66M | -22.65M | -12.50M | -5.77M | -14.30M | 781.10K | 1.61M | -9.21M | -3.80M | -14.03M |
| Income Before Tax Ratio | -28.79% | -58.45% | -45.35% | -34.29% | -19.77% | -13.11% | -43.04% | 2.83% | 7.12% | -156.12% | -53.34% | -102.71% |
| Income Tax Expense | 421.00K | 443.00K | 63.00K | 16.00K | 4.99M | -1.25M | -2.17K | 475.81K | 426.91K | 27.17K | 24.55K | 5.03K |
| Net Income | -23.96M | -47.24M | -31.73M | -22.67M | -12.50M | -4.52M | -14.30M | 305.29K | 1.18M | -9.24M | -3.83M | -14.03M |
| Net Income Ratio | -29.30% | -59.00% | -45.44% | -34.32% | -19.77% | -10.27% | -43.04% | 1.11% | 5.23% | -156.58% | -53.69% | -102.75% |
| EPS | -0.91 | -1.98 | -1.37 | -1.18 | -0.65 | -0.24 | -0.78 | 0.02 | 0.06 | -0.61 | -0.25 | -0.93 |
| EPS Diluted | -0.91 | -1.98 | -1.37 | -1.18 | -0.65 | -0.24 | -0.78 | 0.02 | 0.07 | -0.61 | -0.25 | -0.92 |
| Weighted Avg Shares Out | 26.33M | 23.81M | 23.09M | 19.25M | 19.23M | 18.99M | 18.37M | 16.45M | 19.64M | 15.25M | 15.25M | 15.15M |
| Weighted Avg Shares Out (Dil) | 26.33M | 23.81M | 23.09M | 19.25M | 19.23M | 18.99M | 18.37M | 16.65M | 15.79M | 15.25M | 15.25M | 15.25M |
Theratechnologies Announces the Resignation of One of Its Directors, Mr. Gary Littlejohn
MONTREAL, July 21, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Mr. Gary Littlejohn has resigned from the Board...
Theratechnologies Announces 1-for-4 Reverse Stock Split
- Issued and outstanding common shares to be consolidated on the basis of 1 post-consolidation share for each 4 pre-consolidation shares issued and outstanding, to regain compliance with NASDAQ listing requirements
Theratechnologies Inc. (THTX) Q2 2023 Earnings Call Transcript
Theratechnologies Inc. (THTX) Q2 2023 Earnings Call Transcript
Theratechnologies Reports Second Quarter 2023 Financial Results and Business Updates
MONTREAL, July 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the second quarter...
Theratechnologies to Announce Second Quarter 2023 Financial Results and Provide Business Update
MONTREAL, June 29, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced it will report financial results and provide a business...
Theratechnologies Draws Down on US$20 Million Second Tranche Under its Term Loan Facility With Affiliates of Marathon Asset Management
Proceeds to Be Used to Redeem All of the Outstanding 5.75% Convertible Unsecured Senior Notes This news release constitutes a “designated news release” for the purposes of the Company's prospectus supplement dated December 16, 2021 to its short form base...
Theratechnologies June 13 Oncology Investigator Call to Update Investors & Analysts on Phase 1 Sudocetaxel Zendusortide Trial
MONTREAL, June 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, will hold a video conference call on Tuesday, June 13, 2023,...
Theratechnologies Receives FDA Agreement to Amended Trial Protocol for its Lead PDC Candidate Sudocetaxel Zendusortide
MONTREAL, June 02, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the U.S. Food and Drug Administration (FDA) has...
Theratechnologies to Present Preliminary Safety and Efficacy Data from Phase 1 Trial of Sudocetaxel Zendusortide in Heavily Pretreated Cancer Patients at ASCO 2023
MONTREAL, May 25, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced preliminary efficacy data from a Phase 1 study of...
Theratechnologies Reports on its Annual Meeting of Shareholders
MONTREAL, May 09, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, reported the voting results from its annual meeting of shareholders held...
Source: https://incomestatements.info
Category: Stock Reports